Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 803Carcinoma, Non-Small-Cell Lung 765Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 338Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 234Leukemia, Myeloid, Acute 234Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 132Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Pharyngeal Neoplasms × Clear all
NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Atara Biotherapeutics

Phase 1/2 Terminated
12 enrolled 8 charts
Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡